41 completed, 9 unknown, 8 recruiting, 7 terminated. 72 Phase 3, 22 Phase 2.
Follow Scleroderma, Systemic: new trials by email Literature Review of Scleroderma, Systemic trials Research Report on Scleroderma, Systemic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis BMS-986353, Fludarabine, Cyclophosphamide - Systemic Sclerosis | Phase 3 | Not yet recruiting | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | 92 | 2027-02-03 | 2026-09-18 |
| Efficacy of A Non-Invasive Botulinum Toxin Microneedle Pad for the Treatment of Secondary Raynaud's Phenomenon Botulinum toxin A via microneedle, Control (Normal saline) - Systemic Sclerosis (SSc), Raynaud Disease Secondary to Scleroderma | Phase 3 | Not yet recruiting | Khon Kaen University | 72 | 2026-08-01 | 2026-08-17 |
| A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis Placebo matching nerandomilast formulation 1, Placebo matching nerandomilast formulation 2, Nerandomilast formulation 1 - Systemic Sclerosis | Phase 3 | Recruiting | Boehringer Ingelheim | 448 | 2026-07-27 | 2026-10-14 |
| Topical Cannabidiol Lotion for Pruritus Relief in Scleroderma 10% urea lotion plus 1% cannabidiol, Control - Mediciine, Systemic Sclerosis (SSc) | Phase 3 | Recruiting | Khon Kaen University | 36 | 2025-11-05 | 2025-11-24 |
| Study of the Efficacy of Nintedanib+Tocilizumab in Patients With Systemic Sclerosis and Interstitial Lung Disease Tocilizumab, Nintedanib, Standard therapy - Systemic Sclerosis, Interstitial Lung Disease | Phase 3 | Recruiting | National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland | 86 | 2025-07-01 | 2026-04-08 |
| A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD) (BLISSconneCTD-OLE) Belimumab - Connective Tissue Diseases | Phase 3 | Recruiting | GlaxoSmithKline | 514 | 2024-12-12 | 2026-09-09 |
| RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis CABA-201 - Systemic Sclerosis, Scleroderma | Phase 2 / Phase 3 | Recruiting | Cabaletta Bio | 37 | 2024-07-02 | 2026-10-16 |
| Safety and Efficacy of Baricitinib on Skin Tightening in Diffuse Cutaneous Systemic Sclerosis: A Comparative Study With Methotrexate tab baricitinib 4 mg daily, tab methotrexate 25 mg weekly with folic acid 5 mg weekly - Diffuse Cutaneous Systemic Sclerosis | Phase 3 | Recruiting | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | 24 | 2024-01-01 | 2025-04-20 |
| Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY) Anifrolumab (blinded), Placebo (blinded), Anifrolumab (unblinded, open label) - Systemic Sclerosis, Scleroderma | Phase 3 | Active not recruiting | AstraZeneca | 314 | 2023-11-08 | 2026-09-30 |
| A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis BMS-986278, BMS-986278 Placebo - Progressive Pulmonary Fibrosis | Phase 3 | Active not recruiting | Bristol-Myers Squibb | 1057 | 2023-10-25 | 2026-04-23 |
| A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease Belimumab, Placebo - Systemic Sclerosis Associated Interstitial Lung Disease, Scleroderma, Systemic | Phase 2 / Phase 3 | Recruiting | GlaxoSmithKline | 300 | 2023-09-13 | 2026-09-08 |
| ADRCs in The Treatment of Hand Dysfunction Due to Scleroderma ADRCs, Standard Care, Placebo - Scleroderma, Diffuse | Phase 3 | Unknown | Paracrine, INC. | 174 | 2023-02-28 | 2022-09-28 |
| Clinical Study of Divozilimab in Patients With Systemic Scleroderma Divozilimab, Placebo - Systemic Scleroderma | Phase 3 | Active not recruiting | Biocad | 152 | 2022-12-26 | 2026-06-10 |
| Effectiveness of Cannabinoids on Appetite in Scleroderma CBD oil, Placebo - Systemic Sclerosis, Malnutrition | Phase 3 | Completed | Khon Kaen University | 30 | 2022-11-09 | 2025-02-20 |
| A Study of MT-0551 in Patients With Systemic Sclerosis Inebilizumab, Placebo - Systemic Sclerosis | Phase 3 | Active not recruiting | Tanabe Pharma Corporation | 80 | 2022-07-20 | 2025-12-08 |
| Preventive Effect of Clopidogrel on the Systemic Sclerosis Development Risk clopidogrel treatment, Placebo - Scleroderma, Systemic Sclerosis | Phase 2 / Phase 3 | Recruiting | University Hospital, Bordeaux | 90 | 2022-06-22 | 2026-07-07 |
| COvid-19 Vaccine Booster in Immunocompromised Rheumatic Diseases COVID-19 vaccine - Rheumatoid Arthritis, Autoimmune Rheumatologic Disease | Phase 2 / Phase 3 | Unknown | Paul R Fortin | 287 | 2022-03-09 | 2023-01-17 |
| Rituxmab Versus IL-6 in Treating ILD Rituximab, IL6 inhibitor - Interstitial Lung Disease, Scleroderma | Phase 2 / Phase 3 | Completed | Assiut University | 60 | 2021-12-01 | 2023-11-15 |
| Effects of Fractional CO2 Laser Treatment on Vaginal Symptoms and Sexual Dysfunction in Women With Systemic Sclerosis CO2 Vaginal Laser - Systemic Sclerosis, Vulvovaginal Signs and Symptoms | Phase 2 / Phase 3 | Completed | IRCCS San Raffaele | 16 | 2020-05-01 | 2024-01-30 |
| Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 3) Placebo IV infusion, Iloprost Injection, for intravenous use - Raynaud's Phenomenon Secondary to Systemic Sclerosis | Phase 3 | Completed | Civi Biopharma, Inc. | 198 | 2019-10-14 | 2025-05-25 |
Showing 20 of 72. Sign in to see all of them.
Scleroderma, Diffuse (43) · Raynaud Disease (15) · Lung Diseases, Interstitial (14) · Autoimmune Diseases (7) · Pulmonary Fibrosis (7) · Connective Tissue Diseases (6) · digital ulcers (5) · Arthritis, Rheumatoid (4) · Hypertension, Pulmonary (3) · Scleroderma, Limited (3) · Arthritis (2) · Dermatomyositis (2) · Lupus Erythematosus, Systemic (2) · Mixed Connective Tissue Disease (2)
Skin Diseases (72) · Skin and Connective Tissue Diseases (72) · Connective Tissue Diseases (66) · Respiratory Tract Diseases (20) · Cardiovascular Diseases (19) · Lung Diseases (19) · Vascular Diseases (19) · Embolism and Thrombosis (15) · Livedoid Vasculopathy (15) · Skin Diseases, Vascular (15) · Thrombosis (15) · Pathological Conditions, Signs and Symptoms (14) · Peripheral Vascular Diseases (14) · Pathologic Processes (12)
Cyclophosphamide (8) · Nitroglycerin (5) · Rituximab (5) · tocilizumab (5) · Bosentan (4) · Sildenafil Citrate (3) · Tadalafil (3) · fludarabine (3) · macitentan (3) · nintedanib (3) · Acetylcysteine (2) · Filgrastim (2) · Granulocyte Colony-Stimulating Factor (2) · Iloprost (2) · Immunoglobulins, Intravenous (2)
Actelion (6) · MediQuest Therapeutics (5) · Federal University of São Paulo (4) · Khon Kaen University (4) · Assistance Publique - Hôpitaux de Paris (3) · Johns Hopkins University (3) · Sanjay Gandhi Postgraduate Institute of Medical Sciences (3) · Boehringer Ingelheim (2) · GlaxoSmithKline (2) · Hoffmann-La Roche (2) · Northwestern University (2) · Università Politecnica delle Marche (2) · Allergan (1) · Assiut University (1) · AstraZeneca (1)
United States (29) · France (15) · Japan (13) · Canada (12) · United Kingdom (12) · Italy (11) · Germany (10) · Spain (9) · Brazil (8) · India (8) · Poland (8) · Australia (7) · Belgium (7) · China (7) · Israel (7)
Richard Burt, MD (2) · Vikas Agarwal, MD, DM (2) · Alexandre WS Silva, PhD (1) · Aman Sharma, MD (1) · Anna Abou-Raya (1) · Armando Gabrielli, MD, professor (1) · Armando Gabrielli, MD,professor (1) · Ayumi Yoshizaki, MD, PhD (1) · Carin Dugowson, MD, MPH (1) · Chingching Foocharoen, M.D. (1) · Chingching Foocharoen, MD (1) · Chris Denton, MD (1)
PMID 37929840, PMID 27163986, PMID 33294861, PMID 33765691, PMID 41217519, PMID 16790698, PMID 17717203, PMID 17901414, PMID 17974598, PMID 18641099, PMID 19892673, PMID 20506355, PMID 20708086, PMID 20800376, PMID 20805294, PMID 20837499, PMID 21547897, PMID 22156609, PMID 23418384, PMID 23910617, PMID 25452309, PMID 25995322, PMID 26704522, PMID 26757749, PMID 27156934, PMID 27179107, PMID 28426903, PMID 28544580, PMID 28602891, PMID 28619061, PMID 28664834, PMID 29066464, PMID 29099620, PMID 29298160, PMID 29853453, PMID 29858547, PMID 30383134, PMID 30651141, PMID 31056685, PMID 31112379, PMID 31813058, PMID 32243207, PMID 32612255, PMID 32866440, PMID 33131208, PMID 33142016, PMID 33223487, PMID 33328257, PMID 33412120, PMID 33538094
2023 (4), 2015 (2), 2025 (2), U01HL060839 (1)